TIGIT Inhibitor Clinical Trials Intelligence Report Insight:
- Number of TIGIT Inhibitor Drug In Trials
- TIGIT Inhibitors Trials By Phase, Company, Country, Indication
- Granted Patent Insight
- Clinical Trials Adverse Events Scenario
- Available Financing Information for TIGIT Trials
- Company Agreement/Partnership/Deals For Ongoing Trials
For Report Sample Contact email@example.com
Cancer is a complex set of disease which represents almost one-third of the leading causes of death and disability worldwide. Traditionally, conventional cancer therapies including surgery, radiotherapy, and chemotherapy were the principal treatment modalities. However, the efficacy of these therapies is hampered by many dangerous side effects associated with non-selective cytotoxicity. During the last few years, the paradigm treatment of cancer has been completely revolutionized which is mainly due to identification of several molecular alterations which act as driver for cancer progression and development.
The emergence of PD1/PDL1 immune checkpoint inhibitors has greatly transformed the treatment of multiple cancers. As the field of cancer immunotherapy evolved, researchers have done research and development, their key focus area was the identification of other therapies which can complement PD1/PDL1 inhibitors or target populations which do not respond to them. The relentless efforts have led to identification of TIGIT. TIGIT (T cell immunoreceptor with immunoglobulin and ITIM domains) is an inhibitory receptor, mainly expressed on natural killer (NK) cells and activated T cells and T regulatory cells. It binds to the major ligand CD155 (poliovirus receptor, PVR), mainly expressed on antigen-presenting cells (APC) or tumor cells, to down-regulate T cell and NK cell functions. TIGIT can inhibit innate and adaptive responses in various mechanisms and act as a “brake” like PD-1/PD-L1 does to stop T cells from attacking tumors.
Initial preclinical studies have demonstrated that blocking TIGIT is effective against multiple advanced cancers including non-small cell lung cancer, melanoma, multiple myeloma, and others. To date, cocktail of TIGIT inhibitors have been developed by researchers which are being evaluate in preclinical and clinical trials. Currently, no TIGIT inhibitor has gained approval in the market but a majority of them are present in phase-I/II clinical trials which are expected to enter the market in next 3-years. The promising TIGIT inhibitor candidate includes Tiragolumab, Vibostolimab, Domvanalimab, Etigilimab, EOS448, M6223, and others which are being evaluated for the treatment of wide range of cancers.
The overall market will mainly be restricted by the long duration of drug development and stringent regulatory guidelines. However, as the healthcare sector of majority regions is shifting towards novel therapeutic approach the drug regulatory bodies are providing special provisions and rapid approvals are expected in coming years. In addition, technological advancements in field of science have also enabled to fasten the overall drug development process and reduce the associated cost. Moreover, several biopharmaceutical companies and biotech firms around the world have initiated important alliances including partnerships, collaborations, mergers and several more, dedicated on fueling the entire therapy to launch several potential drugs in forthcoming years. The entire research and growth frontiers associated with the development of TIGIT inhibitor are believed to increase at higher percent during the forthcoming years.
As per our report, it has been analyzed that global TIGIT inhibitor market is currently present at nascent stage as there is no approved drugs available. However, the robust research and development activities and strong pipeline suggests that the market will grow with high CAGR rates in forthcoming years. In addition, increase in prevalence of cancer and unmet need of targeted therapy in its management will also boost the growth of market during forecast period. Keeping in mind the high adoption rates of novel targeted therapy, it is predicted that US will dominate the global TIGIT inhibitor market in future. The high demand in the region will be sustained by factors that include rise in geriatric population associated with increased risk of cancer. Along with it, the presence of large pharmaceutical sector which actively invest in research and development will also drive the market.